Fibroblast growth factor 21 (FGF21), a recently discovered endocrine factor, has an important role in glucose and lipid metabolism and may contribute to the development of atherosclerosis and coronary heart disease. The present crosssectional study examined the relationship of FGF21 with hypertension in 744 community-dwelling adults who participated in the Baltimore Longitudinal Study of Aging (BLSA).
FGF21 is a recently discovered hormone that has been implicated in abnormal glucose metabolism, insulin resistance and dyslipidemia in adults. 1, 2 FGF21 is a member of the family of FGFs, but is atypical in that it lacks a heparin-binding domain, which allows FGF21 to leave the tissues of origin and circulate freely as an endocrine factor. FGF21 is expressed in the liver, white adipose tissue and the pancreas. FGF21 binds to the cell surface receptor FGFR complex formed with b-klotho to stimulate glucose uptake in adipocytes. 1, 2 In animal models, systemic administration of FGF21 increases energy expenditure, reduces body weight and improves lipid profiles by lowering low-density lipoprotein (LDL) cholesterol and increasing high-density lipoprotein (HDL) cholesterol. 1, 2 In contrast to the observations in animal models, in humans, elevated circulating FGF21 is associated with the metabolic syndrome, 3 and dyslipidemia, 4 which suggests that FGF21 expression might be dysregulated becasue of abnormalities in FGF21 secretion or circulating FGF21 isoforms, or FGF21 resistance in peripheral tissues. In adults without diagnosed diabetes, elevated plasma FGF21 is associated with abnormal glucose metabolism, insulin resistance and reduced whole body insulin sensitivity. 5 In adults with type 2 diabetes, elevated FGF21 is associated with the presence of carotid artery plaques. 6 The combination of dyslipidemia and hypertension is associated with an increased risk of atherosclerosis and cardiovascular disease. The underlying causes of hypertension include abnormalities in the renin-angiotensin system, dysregulation in sodium handling and genetic predisposition, but much of the basic pathophysiology remains obscure. 7 In obese women, elevated FGF21 was associated with increased arterial stiffness, as measured by brachial-ankle pulse wave velocity. 8 Arterial stiffness and hypertension have been shown to have a bidirectional association. 9 The relationship of circulating FGF21 with hypertension has not been characterized. Our previous investigations suggested an association between FGF21 and hypertension, but these findings were preliminary. 5 We hypothesized that serum FGF21 is independently associated with hypertension and that FGF21 may be related to hypertension through dyslipidemia. To address this hypothesis, we investigated the relationship of FGF21 with hypertension in community-dwelling adults.
The study subjects consisted of participants in the BLSA, who were seen between April 2002 and August 2007. The BLSA is a prospective open cohort study of community-dwelling volunteers, largely from the Baltimore/Washington area. The study was established in 1958 and is described in detail elsewhere. 10 BLSA participants return every 2 years to the Gerontology Research Center in Baltimore, MD, for 2.5 days of medical, physiological and psychological examinations. Height was measured to the nearest 0.5 cm. Weight was measured to the nearest 0.1 kg. Body mass index (BMI) was calculated as kg m À 2 . Smoking status was ascertained by a questionnaire that classified each subject as a non-smoker, former smoker or current smoker. Diagnosis of hypertension was based upon self-report of physician diagnosis of hypertension and corroboration with current treatment (diuretics, antihypertensive medications) or blood pressure 4140/90 mm Hg. Metabolic syndrome was defined according to recent consensus criteria. 11 The BLSA has continuing approval from the Institutional Review Board of the MedStar Research Institute. The protocol for this study was also approved by the Institutional Review Board of the Johns Hopkins School of Medicine.
Blood samples were drawn from the antecubital vein between 0700 and 0800 hours after an overnight fast. Serum creatinine, glucose, cholesterol and triglycerides were measured as described elsewhere. 5 Chronic kidney disease (stage 3) and fasting plasma glucose were categorized as described elsewhere. 5 Samples were stored continuously at À 70 1C until the time of analysis of serum FGF21. Serum FGF21 was measured using ELISA (Quantikine Human FGF-21 ELISA, R&D Systems, Minneapolis, MN, USA). The samples were analyzed at Johns Hopkins Hospital in the laboratory of one of the investigators (RDS). The intra-and interassay coefficients of variability were 2.8 and 7.0%. The assay has a minimum limit of detection of 4.6 pg ml À 1 . No samples were below the lower limit of detection.
Continuous variables were reported as median (25th, 75th percentile). Serum FGF21 was highly skewed and log-transformed to obtain a normal distribution. Multivariate logistic regression models were used to examine the relationship of log serum FGF21 (per 1 s.d.), demographic, anthropometric and clinical characteristics with hypertension. Covariates included in the multivariable models were traditional risk factors for hypertension (age, race, smoking and body mass index). Diabetes and estimated glomerular filtration rate (eGFR) included in the multivariate models because these two variables are known to be associated with higher FGF21 levels. All analyses were conducted using SAS (version 9.1.3; SAS Institute, Cary, NC, USA) with type I error of 0.05.
Overall, the median (25th, 75th percentile) serum FGF21 concentration was 227 (127, 371) pg ml À 1 . Of the 744 adults, 235 (31.6%) had hypertension. The characteristics of the 744 participants in the study overall and by the presence or absence of hypertension are shown in Table 1 . Age, race, BMI, waist circumference, metabolic syndrome, use of angiotensin-converting enzyme inhibitors, FGF21, triglycerides, fasting plasma glucose, eGFR, chronic kidney disease and diabetes were significantly associated with hypertension. Male gender, current smoking, angiotensin receptor blocker use, total cholesterol, HDL cholesterol, LDL cholesterol and C-reactive proteins were not associated with hypertension. No participants were taking fibrate medications. Median (25th, 75th percentile) FGF21 concentrations in subjects taking or not taking angiotensin-converting enzyme inhibitors, respectively, was 278 (165, 468) and 220 (123, 353) pg ml À 1 (Po0.0001). Log FGF21 (per 1 s.d. increase, 0.77) was significantly associated with hypertension in multivariable logistic regression models adjusting for age, race, smoking and BMI (odds ratio (OR) 1.25; 95% confidence interval (CI): 1.03-1.51, P ¼ 0.02), additionally for eGFR (OR 1.23; 95% CI: 1.01-1.48, P ¼ 0.03) and finally with addition of diabetes (OR 1.22; 95% CI: 1.01-1.48, P ¼ 0.04).
The Spearman correlation between serum FGF21 and triglycerides was 0.31 (Po0.0001). When triglycerides were added to the preceding model, the association between log FGF21 (per 1 s.d. increase) changed (OR 1.17; 95% CI, 0.96-1.43; P ¼ 0.13). We also explored alternative multivariate models for log FGF21 (per 1 s.d. increase) and hypertension adjusting for age, race, smoking, eGFR and fasting plasma glucose (OR 1.20; 95% CI 0.99, 1.46; P ¼ 0.06), or adjusting for age, race, smoking, eGFR, diabetes and dyslipidemia (OR 1.23; 95% CI: 1.01, 1.48; P ¼ 0.04). Log FGF21 (per 1 s.d. increase) was also associated with metabolic syndrome (OR 2.02; 95% CI: 1.52, 2.68, Po0.0001), adjusting for age, race, smoking, eGFR, BMI and diabetes.
This study shows that serum FGF21 levels are independently associated with hypertension in community-dwelling adults. To our knowledge, this is the first study to show that elevated serum FGF21 is independently associated with hypertension in adults. Whether elevated serum FGF21 is causally related to hypertension cannot be determined from this cross-sectional observational study. It is interesting to note that in an intervention study involving 40 non-diabetic obese women, 3 months of supervised exercise training fives times per week led to significant reductions in systolic and diastolic blood pressure, arterial stiffness and circulating FGF21 levels. 8 In 72 patients with end-stage renal disease, angiotensin receptor blocker treatment for 6 months reduced serum FGF21 concentrations by 13%. 12 These findings suggest a possible link between the renin-angiotensin system and FGF21. The strengths of this study include the relatively large sample size of community-dwelling adults, the rigorously timed and standardized collection of fasting serum samples for FGF21 measurements and the adjustment of the multivariable analysis for renal function. A limitation of the study is the cross-sectional design, as the direction of the association of elevated circulating FGF21 and hypertension is not known. As with any epidemiological study, it is not possible to measure all potential confounders, and there may be other unmeasured factors that influence the association between FGF21 and hypertension. Further studies are needed to address the biological mechanism(s) that could explain the association between FGF21 and hypertension.
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The authors declare no conflict of interest. RD Severe and long-lasting hypotension occuring immediately after parathyroidectomy in hypertensive hemodialysis patients: a case series Secondary hyperparathyroidism of hemodialysis patients is associated with hypertension. Parathyroidectomy might cause a mild and gradual decrease in blood pressure. We describe a case series of severe and long-lasting hypotension starting immediately after parathyroidectomy, possibly related to resetting of intracellular calcium levels and attenuation of the vascular response to calcium. Primary, secondary and tertiary forms of hyperparathyroidism are associated with hypertension. 1 Severe secondary hyperparathyroidism is an indication for corrective parathyroidectomy. Some studies have reported that parathyroidectomy induces a mild and gradual drop in blood pressure (5-10 mm Hg). Other studies showed no effect at all. [2] [3] [4] A recent work utilizing 24-h ambulatory blood pressure monitoring concluded that blood pressure increases after parathyroidectomy. 5 However, a substantial hypotensive effect has not yet been reported.
We present a case series of initially hypertensive end stage renal disease (ESRD) patients, who had an abrupt drop in blood pressure immediately after parathyroidectomy of hyperplastic parathyroid glands, leading to postoperative refractory hypotension persisting for months to years. Hypotension was documented at clinical measurements (peridialytic) and at repeated home blood pressure measurements.
Initially, patients underwent a workup for their hypotension to exclude any other cause (unrelated to the parathyroid operation) and to delineate possible mechanisms of parathyroidectomyrelated hypotension. Patients had their supine and orthostatic blood pressure measured by a standard sphyngomanometer (Welch Allyn, Skaneateles Falls, NY, USA) after 5 min of lying down (two measurements) and within 2 min of standing (two measurements). Later, patients had their central (aortic) blood pressure and their pulse wave velocity (PWV) also measured (using SphygmoCor; Atcor Medical, Sydney, New South Wales, Australia). 6, 7 CASE I A 45-year-old man had been on hemodialysis since 29 years of age. His average predialysis blood pressure was 140/90. He had been diagnosed with severe secondary hyperparathyroidism and thus underwent excision of four hyperplastic parathyroid glands 10 years ago. His immediate postoperative blood pressure was 60/40 mm Hg. His calcium and parathyroid hormone (PTH) values dropped abruptly (Table 1 ). In the last 10 years, since the operation, the patient has suffered from symptomatic hypotension, with an average blood pressure of 70/50 mm Hg. He underwent full endocrine evaluation (thyroid stimulating hormone, cortisol and adrenocorticotropic hormone) and cardiac function (echocardiogram), which were all normal. Results of his autonomic function studies suggested a hyperactive (compensatory) adrenergic response. An electromyography revealed only a mild peripheral neuropathy. In addition, his plasma renin activity and aldosterone levels were within normal range for upright position and normal sodium diet. A hemodynamic study (Impedance Cardiography; Bio Z ICG monitor, CardioDynamics, San Diego, CA, USA) revealed cardiac index of 3.8 l min À 1 m À 2 that increased at peak exercise to 8.3 ml min À 1 m À 2 . His systemic vascular resistance (SVR) at rest was low-586 dyn s cm À 5 (normal 742-1378), and decreased even further during exercise-332 at peak exercise. His SVR index was similarly low at rest and during exercise. Trials of increased salt and coffee consumption, increase in sodium dialysate (145 mM), increase in dry weight (less ultrafiltration), increase in calcium dialysate (3 meq l 
CASE II
A 46-year-old female suffered from resistant hypertension since 23 years of age, and was treated originally with clonidine, amlodipine and atenolol. Despite these interventions, she maintained a blood pressure of 180-200/100 mm Hg. Her blood pressure later stabilized after several years of hemodialysis (HD), and she remained only on an alpha blocker (doxazosin). She had longstanding hyperparathyroidism (PTH 7000 pg ml À 1 ) and was referred for parathyroidectomy. Her first surgery involved excision of only one gland. She subsequently underwent a second surgery for residual hyperparathyroidism. Her blood pressure, serum
